Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

Addressing an audience of 150 attendees at its first clinical-stage R&D day on July 11, Verastem Inc. put forward its new senior executive team, as well as an eminent authority in cancer stem cell biology, to describe its clinical progress thus far, and its future plans.

Advertisement

Related Content

Verastem Catapults To Mid-stage Development with Pfizer Licensing Deal
The HDAC Field Heats Up: An Interview with Syndax CEO Joanna Horobin

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel